Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy and safety of a novel pegylated interferon alpha-2a in Egyptian patients with genotype 4 chronic hepatitis C.

Canadian journal of gastroenterology = Journal canadien de gastroenterologie - 1 Oct 2010

Taha Alaa Awad, El-Ray Ahmad, El-Ghannam Maged, Mounir Bahaa

Abstract excerpt

BACKGROUND: Hepatitis C virus (HCV) genotype 4 is a common infection in Egypt and is the leading cause of liver disease. OBJECTIVE: To study the efficacy and safety of a novel 20 kD pegylated interferon alpha-2a derived from Hansenula polymorpha in combination with ribavirin for the treatment of Egyptian patients with genotype 4 chronic hepatitis C (CHC). METHODS: One hundred seven patients with genotype 4 CHC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Therapy, Combination
Share to Egypt

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C, Chronic

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Polyethylene Glycols

Share to Ribavirin

Share to Viral Load

Source

Open in PubMed Open full text

Identifiers

PMID: 21037988
DOI: 10.1155/2010/717845
PMCID: PMC2975472

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy and safety of a novel pegylated interferon alpha-2a in Egyptian patients with genotype 4 chronic hepatitis C.PMID 21037988Read ↗

Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis.Semantic proximity Read ↗

The efficacy of a Hansenula-derived 20 kDa pegylated interferon alpha-2a in the treatment of genotype 4 chronic hepatitis C.Semantic proximity Read ↗

Hepatitis C genotype 4Semantic proximity Read ↗

Effectiveness of Sofosbuvir, Ribavirin and PEG-IFNα-2a in the Treatment of Naïve Egyptian Patients With Chronic Hepatitis C Virus Genotype 4.Semantic proximity Read ↗

Hepatitis C genotype 4 therapy: increasing options and improving outcomes.Semantic proximity Read ↗

A randomized trial of 24 versus 48 weeks of peginterferon alpha-2a plus ribavirin in Egyptian patients with hepatitis C virus genotype 4 and rapid viral response.Semantic proximity Read ↗

Hepatitis C virus genotype 4 therapy: progress and challenges.Semantic proximity Read ↗

Management of hepatitis C virus genotype 4: recommendations of an international expert panel.Semantic proximity Read ↗

The Effect of Peginterferon Alpha-2a vs. Peginterferon Alpha-2b in Treatment of Naive Chronic HCV Genotype-4 Patients: A Single Centre Egyptian StudySemantic proximity Read ↗

Genotype 4 hepatitis C virus-a review of a diverse genotype.Semantic proximity Read ↗

Treatment of chronic hepatitis C genotype 4 with peginterferon alpha-2a plus ribavirin.Semantic proximity Read ↗

Pegylated interferon-alpha2b plus ribavirin for the treatment of chronic hepatitis C virus genotype 4 infection in patients with normal serum ALT.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.